Giant Cell Tumor of Distal End of Femur with Pathological Fracture Treated by Resection and Megaprosthesis: A Case Report


Authors : DR K. RAGHU NATHA REDDY; DR K. VENKATA SUDHAKAR NAIK; DR D. LAKSHMI KANTH; DR. Y.V.SATYANARAYANA

Volume/Issue : Volume 8 - 2023, Issue 1 - January

Google Scholar : https://bit.ly/3IIfn9N

Scribd : https://bit.ly/3YvkO4t

DOI : https://doi.org/10.5281/zenodo.7637993

Giant cell tumor (GCT) is usually a benign tumor of the bone which arises from the metaphysis area and may typically extends into the epiphysis of the long bones. These are neoplasms arising from mesenchymal stromal cells and shows varied manifestations. GCT is considered to be of benign nature but 3% of giant cell tumors of bone are primarily malignant in nature or will undergo malignant transformation and metastasize to lung and other areas. Pathological fracture rates range from 9% to 30% among patients with GCTs of the bone at the time of initial presentation. Due to the lack of definite clinical, radiological, or histological parameters that can accurately predict the progression of the disease, treating this tumour remains a difficult problem. Patients who present with a pathological fracture are frequently thought to have a more aggressive form of disease, which increases their chance of local recurrence and worsens their prognosis. We consider it essential to share a case of a distal femoral GCT with a pathological fracture that was treated by enbloc excision and reconstruction with megaprosthesis with good functional outcome.

Keywords : GCT, Distal femur, Pathological fracture, Megaprosthesis.

CALL FOR PAPERS


Paper Submission Last Date
29 - February - 2024

Paper Review Notification
In 1-2 Days

Paper Publishing
In 2-3 Days

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe